10-Q · May 15, 2026
Cardio Diagnostics reported Q1 revenue of $2,680, marking a significant increase from $940 in the prior year, suggesting improved test adoption. However, operating expenses also grew, leading to a wider net loss of…
Earnings analysis · 10-Q
CDIO earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
The extracted filing does not include the current-quarter income statement, balance sheet or cash-flow amounts, so quarter-over-quarter and year-over-year financial trends cannot be assessed from the available text. The…
Read full summary
The extracted filing does not include the current-quarter income statement, balance sheet or cash-flow amounts, so quarter-over-quarter and year-over-year financial trends cannot be assessed from the available text. The company reported ineffective disclosure controls and a material weakness in segregation of duties that remained under remediation as of June 30, 2026. Listing risk is significant: market value was $4,912,719 versus a proposed $5 million Nasdaq threshold, although the rule was temporarily stayed on July 29, 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Internal-control remediation underway
Management is developing approval matrices requiring dual authorization for significant transactions, including payments above a specified threshold and general-ledger changes. The company is also exploring accounting software with built-in controls.
-
No material litigation reported
The company reported no material litigation as of June 30, 2026, stating that it was not party to litigation material to ongoing operations under Item 103.
What to watch
-
Material weakness in financial controls
Management concluded that disclosure controls and procedures were not effective. The company identified inadequate segregation of duties due to limited staff resources as a material weakness during the six months ended June 30, 2026; remediation had not been fully implemented or tested.
-
Nasdaq listing risk
A proposed Nasdaq standard would require at least $5 million of market value of listed securities, with suspension and delisting after 30 consecutive business days below the threshold. On August 6, 2026, the company’s market value was $4,912,719, based on a $1.66 closing price and 2,959,469 shares outstanding.
-
Potential OTC trading consequences
If delisted, the company expects its securities would trade on the OTC market, where it identifies risks including low liquidity, wider bid-ask spreads and reduced financial transparency. The filing states investors could have difficulty selling shares at their desired price, or at all.
Management's outlook
No quantitative revenue or EPS guidance was provided in the extracted filing. The filing states that remediation efforts were ongoing and had not been fully implemented or tested as of June 30, 2026.
Earlier filings 4
10-K · March 13, 2026
Cardio Diagnostics reported 2025 revenue of $14,825 and a 2025 GAAP loss per share of $(3.71), with Q4 revenue of $3,555 and Q4 EPS of $(0.80). The company continues to commercialize its epigenetics-based tests (Epi+Gen…
10-Q · November 12, 2025
Cardio Diagnostics reported Q3 2025 revenue of $2,855 and a net loss of $1,714,536 (EPS $(0.98)), with revenue down sharply versus the year-ago quarter ($6,580) and operating expenses remaining large ($1,714,452). Cash…
10-Q · May 15, 2025
Cardio Diagnostics Holdings, Inc. reported a significant decline in revenues for Q1 2025, posting only $940 compared to $15,928 in Q1 2024. The company experienced substantial losses, with a reported EPS of -$0.97…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.